NEW YORK (GenomeWeb) – Amoy Diagnostics today announced a deal with biopharmaceutical firm Canbridge Life Sciences to develop a companion diagnostic for Canbridge's lead product, CAN008.

Amoy will supply its CD95 IHC and CpG2 qPCR kits as part of the deal. CAN008 is a fully human Fc fusion protein, and in a previous Phase II trial conducted in Europe, it demonstrated "significant overall survival benefit" for recurrent glioblastoma multiforme patients with high expression of the CD95 ligand, or low methylation of CD95L promotor CpG2, the companies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.